Q-omics provides the consensus-scored LINC01553 profile across patient tissues and cancer cell-line models. LINC01553 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LINC01553 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, LINC01553 RNA expression shows 6,427 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, KICH, and STAD as cancer lineages where LINC01553 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01553 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01553 survival associations across molecular data types. LINC01553 RNA expression shows survival associations in the most cancer types (9), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01553 RNA expression–survival associations across cancer types. High LINC01553 expression shows unfavorable associations in UCEC, BRCA, THYM and TGCT, but favorable associations in COAD and SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for LINC01553 RNA expression.
This table summarizes LINC01553 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01553. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01553 shows lower tumor expression in THCA and higher tumor expression in KICH, READ, LUAD, BRCA and PAAD. The KICH box plot shows higher LINC01553 RNA expression in tumor versus normal tissue (log2 FC = +0.023, t-test p < 0.001).
This table shows molecular features associated with LINC01553 in patient tissues and cancer cell lines. In patient samples, LINC01553 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC01553 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE.
